Mice treated with the dopamine transporter protein inhibitor GBR12909 (15 mg/kg) constitute a validated animal model for BD, whereas germ-free mice are less susceptible to GBR12909 with less mania-like behavior, suggesting that the gut microbiota contributes to the disease progression of BD via the dopaminergic system (de Miranda et al., 2020). Here, SLC6A3 is linked to Behcet disease.